Answers are grounded in this paper and cite their sources.
Narrative review reveals broad cytoprotective mechanisms of erythropoietin across neural and vascular tissues, highlighting therapeutic potential in ischemic disorders.
Discovery that the hormone erythropoietin (EPO) and its receptor play a significant biological role in tissues outside of the hematopoietic system has fueled significant interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems. Erythropoietin is now considered to have applicability in a variety of disorders that include cerebral ischemia, myocardial infarction, and chronic congestive heart failure. Erythropoietin modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis. As a result, cellular protection by EPO is robust and EPO inhibits the apoptotic mechanisms of injury, including the preservation of cellular membrane asymmetry to prevent inflammation. As the investigation into clinical applications for EPO that maximize efficacy and minimize toxicity progresses, a deeper appreciation for the novel roles that EPO plays in the brain and heart and throughout the entire body should be acquired.
No takes yet. Share an insight, caveat, or question.
Kenneth Maiese (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: